A detailed history of David Rolfe (Wedgewood Partners Inc) transactions in Edwards Lifesciences Corp stock. As of the latest transaction made, Wedgewood Partners Inc holds 359,257 shares of EW stock, worth $26.9 Million. This represents 4.54% of its overall portfolio holdings.

Number of Shares
359,257
Previous 354,427 1.36%
Holding current value
$26.9 Million
Previous $32.7 Million 27.59%
% of portfolio
4.54%
Previous 6.52%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$59.7 - $93.78 $288,351 - $452,957
4,830 Added 1.36%
359,257 $23.7 Million
Q2 2024

Aug 13, 2024

BUY
$84.3 - $94.31 $9.19 Million - $10.3 Million
108,976 Added 44.4%
354,427 $32.7 Million
Q1 2024

May 16, 2024

SELL
$72.54 - $95.56 $377,280 - $497,007
-5,201 Reduced 2.07%
245,451 $23.5 Million
Q4 2023

Feb 14, 2024

BUY
$61.71 - $77.76 $3.51 Million - $4.42 Million
56,855 Added 29.34%
250,652 $19.1 Million
Q3 2023

Nov 14, 2023

BUY
$69.28 - $93.38 $13.4 Million - $18.1 Million
193,797 New
193,797 $13.4 Million
Q2 2023

Aug 14, 2023

SELL
$81.41 - $94.33 $1.21 Million - $1.41 Million
-14,897 Reduced 4.51%
315,173 $29.7 Million
Q1 2023

May 15, 2023

SELL
$74.26 - $84.51 $274,019 - $311,841
-3,690 Reduced 1.11%
330,070 $27.3 Million
Q4 2022

Feb 14, 2023

BUY
$68.3 - $87.44 $145,683 - $186,509
2,133 Added 0.64%
333,760 $24.9 Million
Q3 2022

Nov 14, 2022

BUY
$82.37 - $107.29 $27.3 Million - $35.6 Million
331,627 New
331,627 $27.4 Million
Q2 2022

Aug 15, 2022

SELL
$86.5 - $128.27 $1.52 Million - $2.25 Million
-17,531 Reduced 4.89%
340,689 $32.4 Million
Q1 2022

May 16, 2022

BUY
$101.96 - $128.34 $517,039 - $650,812
5,071 Added 1.44%
358,220 $42.2 Million
Q4 2021

Feb 14, 2022

SELL
$106.37 - $130.68 $12.7 Million - $15.6 Million
-119,478 Reduced 25.28%
353,149 $45.7 Million
Q3 2021

Nov 12, 2021

SELL
$102.91 - $122.75 $1.12 Million - $1.34 Million
-10,909 Reduced 2.26%
472,627 $53.5 Million
Q2 2021

Aug 13, 2021

SELL
$83.84 - $104.76 $2.54 Million - $3.18 Million
-30,352 Reduced 5.91%
483,536 $50.1 Million
Q1 2021

May 17, 2021

SELL
$78.68 - $90.67 $6.38 Million - $7.35 Million
-81,068 Reduced 13.63%
513,888 $43 Million
Q4 2020

Feb 12, 2021

SELL
$71.69 - $91.23 $2.64 Million - $3.35 Million
-36,762 Reduced 5.82%
594,956 $54.3 Million
Q3 2020

Nov 13, 2020

SELL
$67.19 - $87.44 $2.47 Million - $3.22 Million
-36,824 Reduced 5.51%
631,718 $50.4 Million
Q2 2020

Aug 14, 2020

BUY
$57.54 - $76.95 $24.8 Million - $33.2 Million
431,342 Added 181.85%
668,542 $46.2 Million
Q1 2020

May 15, 2020

SELL
$52.41 - $81.0 $7.17 Million - $11.1 Million
-136,862 Reduced 36.59%
237,200 $44.7 Million
Q4 2019

Feb 14, 2020

SELL
$71.7 - $82.09 $7.51 Million - $8.6 Million
-104,727 Reduced 21.87%
374,062 $87.3 Million
Q3 2019

Nov 14, 2019

SELL
$61.55 - $75.43 $2.55 Million - $3.13 Million
-41,504 Reduced 7.98%
478,789 $105 Million
Q2 2019

Aug 14, 2019

SELL
$55.74 - $64.41 $7.83 Million - $9.05 Million
-140,526 Reduced 21.27%
520,293 $96.1 Million
Q1 2019

May 15, 2019

SELL
$47.89 - $64.05 $7.68 Million - $10.3 Million
-160,313 Reduced 19.52%
660,819 $126 Million
Q4 2018

Feb 14, 2019

BUY
$46.41 - $56.94 $100,802 - $123,673
2,172 Added 0.27%
821,132 $126 Million
Q3 2018

Nov 14, 2018

SELL
$45.7 - $58.03 $3.31 Million - $4.2 Million
-72,450 Reduced 8.13%
818,960 $143 Million
Q2 2018

Aug 14, 2018

SELL
$42.45 - $51.3 $48.1 Million - $58.1 Million
-1,132,341 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$37.19 - $47.45 $7.71 Million - $9.84 Million
-207,421 Reduced 15.48%
1,132,341 $158 Million
Q4 2017

Feb 14, 2018

SELL
$33.79 - $39.39 $111,000 - $129,396
-3,285 Reduced 0.24%
1,339,762 $151 Million
Q3 2017

Nov 14, 2017

BUY
$36.29 - $38.83 $48.7 Million - $52.2 Million
1,343,047
1,343,047 $147 Million

Others Institutions Holding EW

About Edwards Lifesciences Corp


  • Ticker EW
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 618,259,968
  • Market Cap $46.3B
  • Description
  • Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair...
More about EW
Track David Rolfe's Portfolio

Track David Rolfe Portfolio

Follow David Rolfe (Wedgewood Partners Inc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wedgewood Partners Inc, based on Form 13F filings with the SEC.

News

Stay updated on Wedgewood Partners Inc and David Rolfe with notifications on news.